NCT00037869View on ClinicalTrials.gov

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Neuroendocrine TumorsMetastases, Neoplasm
Interventions
DRUG

I-131 Metaiodobenzylguanidine

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00037869 - High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter